Navigation Links
Sinovac Announces Closing of Common Share Offering
Date:2/2/2010

BEIJING, Feb. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA) ("Sinovac" or the "Company"), a leading China-based vaccine manufacturer, announced today that its previously announced public common share offering was closed on February 2, 2010. Sinovac received net proceeds of approximately $62.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, which included net proceeds from the sale of 1,500,000 common shares pursuant to the full exercise of the underwriters' over-allotment option.

UBS Securities LLC and Piper Jaffray & Co. served as joint bookrunners for the offering.

The offering was made under Sinovac's currently effective shelf registration statements on Form F-3 filed with the Securities and Exchange Commission on November 18, 2009 and January 27, 2010. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, securities, and does not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained from UBS Securities LLC, Attention: Prospectus Department, 299 Park Avenue, New York, NY 10171, U.S.A., telephone: 888-827-7275, or Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, Suite 800, Minneapolis MN 55402, U.S.A., telephone: 1-800-754-4781.


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Sinovac Announces Exercise of Over-Allotment Option
2. Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government
3. Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea
4. Sinovacs H1N1 Vaccine Passes Experts Evaluation Organized by SFDA
5. Sinovac Wins Beijing Public Health Bureaus Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
6. Sinovac Reports Unaudited Second Quarter 2009 Financial Results
7. Sinovac Schedules 2008 Annual General Meeting
8. Sinovac Reports Unaudited First Quarter 2009 Financial Results
9. Sinovac Announces that Government Investigation Rules Out Healives Role in Childs Death
10. Sinovac Provides Support to Chinas Ministry of Health to Aid Earthquake Victims
11. Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 28, 2015 , ... North ... California in the fall of 2015 . These seventeen courses are pre-approved ... , Optimizing Functional Mobility in the Older Adult , August 22, ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... for Invisalign. Invisalign is a revolutionary orthodontic treatment that allows patients to straighten ... Mozafari’s expertise and 3D computer imaging technology. You wear each set of aligners ...
(Date:7/27/2015)... ... 28, 2015 , ... Dr. Robert G. Schwartz , principal of Greenville, ... with Realief Neuropathy Centers in order to offer his patients a new system of ... of peripheral neuropathy. , Peripheral neuropathy is a disease caused by damage to the ...
(Date:7/27/2015)... ... July 28, 2015 , ... Conducting Advanced Root ... to Improve the Quality of Investigations , **Presented by FDAnews and Learning Plus**, ... CAPAs have been the #1 reason for 483 observations since 1997! , The ...
(Date:7/27/2015)... , ... July 28, 2015 , ... The National ... inductee into the NAPW VIP Woman of the Year Circle. She is recognized with ... 200 operating Local Chapters, NAPW is the nation’s leading networking organization exclusively for professional ...
Breaking Medicine News(10 mins):Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 2Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 3Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 4Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 5Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 6Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 7Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 8Health News:Cupertino Invisalign Dentist, Dr. Setareh Mozafari, is Now Offering Complimentary Consultations for Invisalign 2Health News:Piedmont Physical Medicine & Rehabilitation, P.A. Partners with Realief® Neuropathy Centers to Offer Peripheral Neuropathy Laser Treatment 2Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 2Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 3Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 4Health News:NAPW Inducts Deana Skidmore, Assistant Director of Nursing at Wilton Meadows Rehablilitation and Health Care Center, Into its VIP Woman of the Year Circle 2
... Still Has No System to Monitor MRSA in ... WASHINGTON, Dec. 3 A new study published ... Emerging Infectious,Diseases links a new strain of methicillin-resistant ... more than 20 percent of all human MRSA,infections ...
... LipoScience, Inc. is pleased to,announce the election of ... Mr. Landon has over 30 years of broad, multi-functional ... management, Mr. Landon,was Vice President & General Manager of ... for all of DuPont,s Medical,Products businesses, with total sales ...
... Neuro Kinetics, Inc., (http://www.neuro-kinetics.com ), manufacturers ... for balance, vestibular and neurological disorder,tests, ... has been appointed clinical director,audiology., ... testing, coordination of multi-,site research projects, ...
... Oncology (ESMO) is calling on European politicians to voice their ... receive the best possible treatment. , At a meeting ... States met in Brussels to consider the status of medical ... Such recognition is an essential step in providing optimal treatment ...
... with stimulants, antidepressants and other psychiatric drugs is ... lack of clinical practice guidelines. In a first ... professionals from the Bradley Hasbro Childrens Research Center ... specific disorders to help clinicians who are considering ...
... beat out college students in tests involving digits 1 through ... -- It may be a case of monkey see, monkey ... human adults at remembering numbers. , A team of Japanese ... had learned how to identify the numbers 1 through 9 ...
Cached Medicine News:Health News:New Study Links Animal Agriculture to More Than 20% of MRSA Infections in the Netherlands 2Health News:Neuro Kinetics Appoints Dr. Terri Ives Clinical Director, Audiology 2Health News:Cancer patients to be treated by qualified professionals 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 3Health News:Chimps Top Humans in Number Recall 2
(Date:7/27/2015)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that it ... June 30, 2015, on Thursday, August 6, 2015, after the ... 4:30 p.m. Eastern Time to discuss the financial results and ... Conference Call Details To access the live conference call on ... please dial 877-703-6106 from the United States ...
(Date:7/27/2015)... IRVINE, Calif. , July 27, 2015 ... ELOS ) , a global market leader in ... has received Korean Ministry of Food and Drug Safety ... this regulatory clearance, the Company can fulfill PicoWay orders ... activity in Korea anticipated later in the third quarter ...
(Date:7/27/2015)... YORK , July 27, 2015  Relmada ... novel therapies for the treatment of chronic pain, ... Trial Application (CTA) with Heath Canada ... study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate ... of neuropathic pain. "We are very ...
Breaking Medicine Technology:Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 4Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone 2Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone 3
... NEW YORK, June 3 Delcath Systems, Inc.,(Nasdaq: ... Center of,Bethlehem, PA, part of St. Luke,s Hospital & ... trial for the treatment of,inoperable metastatic melanoma in the ... the isolated, high dose,delivery of the anti-cancer agent melphalan. ...
... Data Presented at ASCO Show 26% Partial Response, 63% Clinical Benefit ... ... Calif., June 3 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... antitumor activity in a Phase 2,trial when administered in combination with ...
Cached Medicine Technology:Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 2Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 2Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 4Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 5Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 6
Silicone Elastomer-Coated Latex Foley Catheters 2-Way...
Silicone Foley Catheters 3-Way...
Midstream Catch Kits...
... The BladderScan® BVI 6300 Bladder Monitor ... prescribed by the healthcare provider to ... on an ongoing basis. It is ... accurate results, so the patient can ...
Medicine Products: